Highlights
- Market Cap
- $9.11B
- Enterprise Value
- -$4.62B
- EPS (TTM)
- $0.57
- PE Ratio
- 19.28
- Total Revenue (TTM)
- $22.35B
- Gross Profit (TTM)
- $17.67B
- EBITDA (TTM)
- $1.26B
- Year Range
- $5.00 - $15.12
- ROA (TTM)
- 1.92%
- ROE (TTM)
- 3.71%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Innovent Biologics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Innovent Biologics, Inc (IVBXF) has returned 12.68% so far this year and 86.20% over the past 12 months.
Innovent Biologics, Inc
- 1D
- 9.86%
- 1M
- -2.74%
- YTD
- 12.68%
- 6M
- -10.32%
- 1Y
- 86.20%
- 3Y*
- 32.06%
- 5Y*
- 3.73%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 4, 2019, IVBXF's average daily return is +0.19%, while the average monthly return is +3.03%. At this rate, your investment would double in approximately 1.9 years.
Historically, 51% of months were positive and 49% were negative. The best month was Dec 2020 with a return of +47.5%, while the worst month was Dec 2021 at -37.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, IVBXF closed higher 19% of trading days. The best single day was Oct 26, 2020 with a return of +53.3%, while the worst single day was Sep 9, 2021 at -40.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.67% | 8.61% | -2.74% | 12.68% | |||||||||
| 2025 | -5.56% | 21.96% | 13.82% | 1.27% | 30.65% | 32.35% | 21.18% | -4.15% | 2.08% | -13.06% | 13.66% | -19.45% | 116.67% |
| 2024 | -17.78% | 34.49% | -10.11% | 0.61% | -8.74% | 4.84% | 2.28% | 9.03% | 16.76% | -25.48% | 6.17% | -7.22% | -8.54% |
| 2023 | 27.19% | -12.48% | 0.00% | 0.84% | -1.45% | -15.82% | -2.01% | -9.21% | 40.85% | 17.70% | -1.27% | -15.32% | 14.82% |
| 2022 | -32.11% | 3.78% | -16.65% | -9.91% | -6.15% | 39.65% | 5.19% | -4.93% | -8.00% | -4.72% | 11.27% | 8.48% | -26.63% |
| 2021 | 26.83% | -9.31% | -22.39% | 42.08% | -7.69% | -0.83% | 0.00% | -11.76% | -4.76% | -8.20% | 1.74% | -37.47% | -43.02% |
Benchmark Metrics
Innovent Biologics, Inc has an annualized alpha of 58.48%, beta of 0.12, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 05, 2019.
- This stock captured 18.63% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -97.15%) — a profile typical of hedging or uncorrelated assets.
- Beta of 0.12 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 58.48%
- Beta
- 0.12
- R²
- 0.00
- Upside Capture
- 18.63%
- Downside Capture
- -97.15%
Return for Risk
Risk / Return Rank
IVBXF ranks 80 for risk / return — in the top 80% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Innovent Biologics, Inc (IVBXF) and compare them to a chosen benchmark (S&P 500 Index).
| IVBXF | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.28 | 0.90 | +0.38 |
Sortino ratioReturn per unit of downside risk | 2.04 | 1.39 | +0.65 |
Omega ratioGain probability vs. loss probability | 1.31 | 1.21 | +0.10 |
Calmar ratioReturn relative to maximum drawdown | 2.74 | 1.40 | +1.34 |
Martin ratioReturn relative to average drawdown | 5.70 | 6.61 | -0.90 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore IVBXF risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Innovent Biologics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Innovent Biologics, Inc was 82.96%, occurring on May 13, 2022. Recovery took 826 trading sessions.
The current Innovent Biologics, Inc drawdown is 20.18%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -82.96% | Jan 25, 2021 | 330 | May 13, 2022 | 826 | Sep 3, 2025 | 1156 |
| -46.54% | Oct 27, 2020 | 23 | Nov 27, 2020 | 35 | Jan 20, 2021 | 58 |
| -31.5% | Sep 5, 2025 | 95 | Jan 21, 2026 | — | — | — |
| -27.63% | Jul 1, 2020 | 12 | Jul 22, 2020 | 60 | Oct 15, 2020 | 72 |
| -20.93% | Mar 16, 2020 | 1 | Mar 16, 2020 | 6 | Apr 16, 2020 | 7 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Innovent Biologics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Innovent Biologics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for IVBXF, comparing it with other companies in the Biotechnology industry. Currently, IVBXF has a P/E ratio of 19.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IVBXF relative to other companies in the Biotechnology industry. Currently, IVBXF has a P/S ratio of 0.6. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IVBXF in comparison with other companies in the Biotechnology industry. Currently, IVBXF has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |